Gene therapy trial for Stargardt disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Stargardt disease type 1 caused by changes in both copies of the ABCA4 gene.
- You must be between 12 and 65 years old (or older if the study doctor agrees).
- You cannot have had any eye surgery in the past 90 days.
- You must stop taking vitamin A or beta-carotene supplements during the study.
- Women who can become pregnant must use birth control for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.